Indian Pharma Giants Recall Products in US Amid Manufacturing Issues

Indian pharmaceutical giants have initiated recalls of their products from the US market due to manufacturing concerns. Dr Reddy's Laboratories, Sun Pharma, Aurobindo Pharma, and FDC Ltd are among the companies listed in the latest Enforcement Report of the US Food and Drug Administration (USFDA).

Dr Reddy's Laboratories, Inc., headquartered in Princeton, New Jersey, is recalling Javygtor (sapropterin dihydrochloride) Powder for Oral Solution (100mg) due to its classification as a "sub-potent drug" according to the USFDA. Additionally, another lot of sapropterin dihydrochloride is being recalled for the same reason. The Class I recall was initiated by the company on April 8 of this year.

Sun Pharma, a prominent player in the pharmaceutical industry, is recalling 11,016 vials of Amphotericin B Liposome for Injection, a medication used in the treatment of fungal infections. The recall, categorised as Class II, was initiated on April 19 due to "out of specification for assay," as stated by the USFDA.

Similarly, Aurobindo Pharma is recalling 13,605 bottles of Clorazepate Dipotassium Tablets (3.75 mg and 7.5 mg), prescribed for anxiety treatment, on the American market. The recall, also classified as Class II, is attributed to "Discoloration: Dotted and yellow spots on tablets." The affected lot was recalled by the company's US-based arm on April 24 of this year.

Another significant recall involves FDC Ltd, which is recalling 3,82,104 units of Timolol Maleate Ophthalmic Solution, a medication used to treat glaucoma, in the American market due to "Defective Container," as specified by the USFDA.

The USFDA states that a Class II recall is started when there is a remote chance of substantial adverse health effects or when using or being exposed to a product that violates regulations and could have short-term or medically reversible negative health effects.

The largest market for pharmaceutical products is the US, where the generic medication market is expected to be valued at approximately USD 115.2 billion in 2019. The recalls by these Indian pharmaceutical companies underscore the importance of stringent quality control measures in the manufacturing process to ensure the safety and efficacy of medications.

These recalls also highlight the collaborative efforts between regulatory authorities like the USFDA and pharmaceutical companies to monitor and address any issues that may arise in the production and distribution of pharmaceutical products.

It is imperative for pharmaceutical companies to uphold the highest standards of quality and compliance to maintain consumer trust and confidence in the integrity of their products. Adherence to regulatory guidelines and proactive measures to address manufacturing issues are crucial steps in safeguarding public health and ensuring the uninterrupted availability of safe and effective medications on the market.

As the pharmaceutical industry continues to evolve and expand globally, it is essential for companies to prioritise quality assurance and regulatory compliance to uphold their reputation and fulfil their commitment to public health and safety.

News Agency Inputs